Transcranial Pulse Stimulation (TPS) in Post-COVID-19

This clinical trial aims to investigate the treatment efficacy of transcranial pulse stimulation (TPS) using the NEUROLITH device (Storz Medical AG, Tägerwilen, Switzerland) in individuals with neurological post-COVID-19-symptoms. TPS is a novel brain stimulation therapy based on non-invasive ultrasound pulses and first published in 2019 by the Medical University of Vienna, Austria (Beisteiner et al. Advanced Science, 2019). The study employs a double-blind, randomized, placebo-controlled design with parallel groups (verum vs. sham). The anticipated timeframe for the entire study is 2 years, during which each participant is expected to be actively engaged for a period of 3-4 months. The aim is to include 102 patients. The randomization ratio is 1:1, ensuring an even distribution between the verum (active treatment) and sham (placebo) groups. Three assessment points are scheduled (Baseline, PostStim, 1monthPostStim). Furthermore, to determine potential effects over time, limited data collection (involving only FIS, BDI-II, SF-36 and BI-PEM) is planned at later time points, specifically at 3 months post-stimulation, 6 months post-stimulation, 12 months post-stimulation, and 24 months post-stimulation.

Hypotheses

• H0: There is no significant difference in the effectiveness of transcranial pulse stimulation (TPS) and placebo treatment in improving primary and secondary endpoints.
• H1: There is a significant difference in the effectiveness of transcranial pulse stimulation (TPS) and placebo treatment in improving primary and secondary endpoints.

Timeline

Each study participant will undergo the following sequence:

• Initial information session and clarification of relevant medical findings regarding inclusion and exclusion criteria
• Baseline screening:

• 3-4 assessment sessions per patient within 14 days, including informed consent
• Patients who do not meet the predefined cut-off values for BDI, FIS, and MoCA will be excluded from subsequent study phases
• Transcranial pulse stimulation

• 5 stimulations per patient within 10 days
• One stimulation per day lasting approximately 30 minutes.
• Post-stimulation assessment (PostStim)

• Conducted during the week following brain stimulation
• 2-3 assessment sessions per patient within 7 days
• One-month post-stimulation assessment (1monthPostStim)

• Conducted one month after brain stimulation
• 2-3 assessment sessions per patient within 7 days

Deviations of + 5 days from the intended timeline are considered tolerable.

Sample Size Calculation

The sample size calculation conducted with G*Power incorporated a small effect size (f = .10), α error probability of .05, and a power of 0.8, resulting in an estimate of 102 patients.

Important note: Originally, the study was designed as a multicenter study with the still-existing Austrian center (N=90) and an Italian center (N=30). Since study realization at the Italian center was ultimately not possible, the trial was streamlined to a single-center design. Consequently, enrollment at the Austrian center was refined so that at least 102 participants would reach the primary endpoint, thus meeting the original sample-size requirement. This administrative change was made prior to any analyses and does not affect the prespecified endpoints or procedures.

Inclusion criteria

• Signed written informed consent
• PCR-confirmed SARS-CoV-2 infection, laboratory confirmed antibody detection for SARS-CoV-2, or physician-verified COVID-19 infection
• At least 12 months after initial SARS-CoV-2 infection that led to Post-COVID (subsequent SARS-CoV-2 infections are not a reason for exclusion)
• Diagnosis of Post-COVID Syndrome or independent suspected diagnosis of Post-COVID Syndrome (Considering that physicians generally hesitate to provide clear-cut Post-COVID diagnoses, a tentative diagnosis by an independent general practitioner or a specialist in a field associated with Post-COVID will suffice for entering this study)
• Age: 20-80
• Evidence of a negative pregnancy test if medically adequate

Exclusion criteria

• Clinically relevant realization of pre-COVID diseases with similar symptoms as Post-COVID
• MoCA score <17 (cut-off for dementia)
• BDI-II score ≥29 (cut-off for severe depression)
• FIS <10 (cut-off for no fatigue)
• Brain implants
• Non-MR-compatible metal parts in the body
• Metal parts in the head
• Use of anticoagulants
• Non-MR-compatible claustrophobia
• Non-MR-compatible pacemaker
• Pregnant and breastfeeding women
• Clinically relevant history of surgery on the head, heart, or vessels
• Relevant corticosteroid treatments administered within 6 weeks prior to the first application
• Tumor of the head if relevant for treatment
• Blood clotting disorders
• Participation in other studies